Showing results (1-10 of 1,981) with videos related to
Sort By:
Pageof 199
Oncogene|July 13, 2010
Drug resistance in mutant FLT3-positive AMLE Weisberg, M Sattler, A Ray, et al.Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|August 22, 2001
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patientsE Weisberg, J D GriffinBlood|May 29, 2000
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell linesE Weisberg, J D GriffinBritish Journal of Cancer|June 21, 2019
Correction: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLE Weisberg, P Manley, J Mestan, et al.British Journal of Cancer|May 25, 2006
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABLE Weisberg, P Manley, J Mestan, et al.International Journal of Hematology|May 10, 2001
Mechanisms of transformation by the BCR/ABL oncogeneM Sattler, J D GriffinCritical Reviews in Oncogenesis|January 1, 1997
Role of focal adhesion proteins in signal transduction and oncogenesisE Weisberg, M Sattler, D S Ewaniuk, et al.Blood|April 6, 2001
ARG tyrosine kinase activity is inhibited by STI571K Okuda, E Weisberg, D G Gilliland, et al.Leukemia|September 20, 2011
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasmsA Deshpande, M M Reddy, G O M Schade, et al.Leukemia|August 24, 2011
The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activityM M Reddy, M S Fernandes, A Deshpande, et al.Pageof 199